Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by SanFrancisco99on Mar 15, 2015 6:21pm
207 Views
Post# 23523505

RE:RE:RE:RE:RE:RE:RE:RE:Amazing Few Weeks: Winter Surprise for RVX

RE:RE:RE:RE:RE:RE:RE:RE:Amazing Few Weeks: Winter Surprise for RVXWell put JKJ.

I would personally not want to take an (expensive) injectible drug - and one that could have cognitive problems as well.  Sounds like a bad idea to my non medical mind.

This info might just help to push our stock price higher this week.  More and more the little pill from Calgary seems to be the last new cardiac drug standing.  Don has hinted for a long time that both the CETP inhibitors and the PCSK9 formulas have issues (as I recall).  Sounds like he has been shown to be right so far.

I'm sure there's been a lot of arrogance in the big cities where the big drug companies are headquartered.  How could a little company from Calgary create such a wonder drug????  But I'd guess that many of those with such arrogant opinions are being converted over to our side.  Especially so lately....
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities